NICHOLE LAMB: Open Payments
NPI 1235746389 · BATTLE CREEK, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$733 in 42 payments from 17 companies in 2025. Trend: 2023 $846 · 2024 $590 · 2025 $733
Food & beverage: $733
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 13 | $181 |
| E.R. Squibb & Sons, L.L.C. | 3 | $64 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $61 |
| Neurocrine BioSciences, Inc. | 3 | $60 |
| GlaxoSmithKline, LLC. | 4 | $59 |
| Otsuka America Pharmaceutical, Inc. | 2 | $54 |
| Amgen Inc. | 3 | $47 |
| Teva Pharmaceuticals USA, Inc. | 2 | $39 |
| Astellas Pharma US Inc | 1 | $21 |
| AstraZeneca Pharmaceuticals LP | 1 | $20 |
Products named: VRAYLAR, COBENFY, QULIPTA, CAPLYTA, INGREZZA, TRELEGY ELLIPTA, REXULTI, UBRELVY.
Industry payments across MI — which companies pay providers there.
